Development of vaccines for Plasmodium vivax malaria (Q38597276)

4 September 2017

Development of vaccines for Plasmodium vivax malaria (English)

1 reference

4 September 2017

0 references

0 references

1 reference

1

Ivo Mueller

1 reference

4 September 2017

Ahmad Rushdi Shakri

2

1 reference

PubMed ID

26428453

4 September 2017

Chetan E Chitnis

series ordinal

3

1 reference

PubMed ID

26428453

4 September 2017

language of work or name

English

0 references

publication date

28 September 2015

1 reference

4 September 2017

1 reference

4 September 2017

33

1 reference

4 September 2017

7489-7495

1 reference

4 September 2017

52

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.060

4 September 2017

1 reference

Key gaps in the knowledge of Plasmodium vivax, a neglected human malaria parasite

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.060

Relapses contribute significantly to the risk of Plasmodium vivax infection and disease in Papua New Guinean children 1-5 years of age.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.060

Determinants of relapse periodicity in Plasmodium vivax malaria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.060

Diagnosis and treatment of Plasmodium vivax malaria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.060

Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.060

Systematic review of sub-microscopic P. vivax infections: prevalence and determining factors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.060

Epidemiology of disappearing Plasmodium vivax malaria: a case study in rural Amazonia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.060

Infectious reservoir of Plasmodium infection in Mae Hong Son Province, north-west Thailand

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.060

Multidrug-resistant Plasmodium vivax associated with severe and fatal malaria: a prospective study in Papua, Indonesia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.060

Plasmodium vivax and mixed infections are associated with severe malaria in children: a prospective cohort study from Papua New Guinea

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.060

Evidence and implications of mortality associated with acute Plasmodium vivax malaria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.060

Plasmodium vivax: clinical spectrum, risk factors and pathogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.060

Severe Plasmodium vivax malaria, Brazilian Amazon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.060

The dominant Anopheles vectors of human malaria in the Americas: occurrence data, distribution maps and bionomic précis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.060

The dominant Anopheles vectors of human malaria in the Asia-Pacific region: occurrence data, distribution maps and bionomic précis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.060

The dominant Anopheles vectors of human malaria in Africa, Europe and the Middle East: occurrence data, distribution maps and bionomic précis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.060

Differential patterns of infection and disease with P. falciparum and P. vivax in young Papua New Guinean children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.060

The risk of malarial infections and disease in Papua New Guinean children.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.060

Longitudinal study of Plasmodium falciparum and Plasmodium vivax in a Karen population in Thailand

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.060

The interaction between Plasmodium falciparum and P. vivax in children on Espiritu Santo island, Vanuatu

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.060

Malariotherapy--insanity at the service of malariology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.060

Natural acquisition of immunity to Plasmodium vivax: epidemiological observations and potential targets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.060

Plasmodium vivax: Correlation of circumsporozoite precipitation (CSP) reaction with sporozoite-lnduced protective immunity in man

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.060

Transmission blocking immunity to human Plasmodium vivax malaria in an endemic population in Kataragama, Sri Lanka

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.060

Infectivity of asymptomatic Plasmodium-infected human populations to Anopheles dirus mosquitoes in western Thailand

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.060

Plasmodium vivax: transmission-blocking immunity in a malaria-endemic area of Colombia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.060

Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.060

Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.060

A novel chimeric Plasmodium vivax circumsporozoite protein induces biologically functional antibodies that recognize both VK210 and VK247 sporozoites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.060

Comparison of the immune responses induced by soluble and particulate Plasmodium vivax circumsporozoite vaccine candidates formulated in AS01 in rhesus macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.060

Protective efficacy of a Plasmodium vivax circumsporozoite protein-based vaccine in Aotus nancymaae is associated with antibodies to the repeat region

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.060

Enhancing humoral responses to a malaria antigen with nanoparticle vaccines that expand Tfh cells and promote germinal center induction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.060

Antigen-displaying lipid-enveloped PLGA nanoparticles as delivery agents for a Plasmodium vivax malaria vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.060

Use of long synthetic peptides to study the antigenicity and immunogenicity of the Plasmodium vivax circumsporozoite protein.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.060

Safety and elicitation of humoral and cellular responses in colombian malaria-naive volunteers by a Plasmodium vivax circumsporozoite protein-derived synthetic vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.060

Phase I safety and immunogenicity trial of Plasmodium vivax CS derived long synthetic peptides adjuvanted with montanide ISA 720 or montanide ISA 51

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.060

Efficacy of a Plasmodium vivax malaria vaccine using ChAd63 and modified vaccinia Ankara expressing thrombospondin-related anonymous protein as assessed with transgenic Plasmodium berghei parasites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.060

Targeting the Plasmodium vivax Duffy-binding protein.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.060

Identification of the erythrocyte binding domains of Plasmodium vivax and Plasmodium knowlesi proteins involved in erythrocyte invasion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.060

Plasmodium vivax invasion of human erythrocytes inhibited by antibodies directed against the Duffy binding protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.060

Plasmodium vivax clinical malaria is commonly observed in Duffy-negative Malagasy people

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.060

Mapping binding residues in the Plasmodium vivax domain that binds Duffy antigen during red cell invasion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.060

Conserved residues in the Plasmodium vivax Duffy-binding protein ligand domain are critical for erythrocyte receptor recognition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.060

Structural basis for Duffy recognition by the malaria parasite Duffy-binding-like domain.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.060

Glycan masking of Plasmodium vivax Duffy Binding Protein for probing protein binding function and vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.060

Dimerization of Plasmodium vivax DBP is induced upon receptor binding and drives recognition of DARC

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.060

Naturally acquired Duffy-binding protein-specific binding inhibitory antibodies confer protection from blood-stage Plasmodium vivax infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.060

Preclinical assessment of the receptor-binding domain of Plasmodium vivax Duffy-binding protein as a vaccine candidate in rhesus macaques.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.060

Targeting TLRs expands the antibody repertoire in response to a malaria vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.060

Mapping epitopes of the Plasmodium vivax Duffy binding protein with naturally acquired inhibitory antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.060

Design and immunogenicity of a novel synthetic antigen based on the ligand domain of the Plasmodium vivax duffy binding protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.060

A multifunctional serine protease primes the malaria parasite for red blood cell invasion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.060

Immunogenicity of a recombinant protein containing the Plasmodium vivax vaccine candidate MSP1(19) and two human CD4+ T-cell epitopes administered to non-human primates (Callithrix jacchus jacchus).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.060

Immunogenicity of Plasmodium vivax combination subunit vaccine formulated with human compatible adjuvants in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.060

Naturally acquired immune responses to P. vivax merozoite surface protein 3α and merozoite surface protein 9 are associated with reduced risk of P. vivax malaria in young Papua New Guinean children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.060

High levels of IgG3 anti ICB2-5 in Plasmodium vivax-infected individuals who did not develop symptoms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.060

A role for apical membrane antigen 1 during invasion of hepatocytes by Plasmodium falciparum sporozoites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.060

Long-term humoral and cellular immune responses elicited by a heterologous Plasmodium vivax apical membrane antigen 1 protein prime/adenovirus boost immunization protocol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.060

Invasion-inhibitory antibodies elicited by immunization with Plasmodium vivax apical membrane antigen-1 expressed in Pichia pastoris yeast

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.060

Antibodies to malaria vaccine candidates Pvs25 and Pvs28 completely block the ability of Plasmodium vivax to infect mosquitoes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.060

Immunogenicity in rhesus of the Plasmodium vivax mosquito stage antigen Pvs25H with Alhydrogel and Montanide ISA 720.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.060

Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.060

Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.060

Antibodies to a single, conserved epitope in Anopheles APN1 inhibit universal transmission of Plasmodium falciparum and Plasmodium vivax malaria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.060

A reliable ex vivo invasion assay of human reticulocytes by Plasmodium vivax

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.060

Hematopoietic stem/progenitor cell sources to generate reticulocytes for Plasmodium vivax culture

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.060

A microscale human liver platform that supports the hepatic stages of Plasmodium falciparum and vivax

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.060

Persistence and activation of malaria hypnozoites in long-term primary hepatocyte cultures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.060

Plasmodium vivax liver stage development and hypnozoite persistence in human liver-chimeric mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.060

Successful sporozoite challenge model in human volunteers with Plasmodium vivax strain derived from human donors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.060

Consistent safety and infectivity in sporozoite challenge model of Plasmodium vivax in malaria-naive human volunteers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.060

Experimentally induced blood-stage Plasmodium vivax infection in healthy volunteers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.060

The neglected burden of Plasmodium vivax malaria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.060

inferred from DOI database lookup

7 January 2021

based on heuristic

Baculovirus merozoite surface protein 1 C-terminal recombinant antigens are highly protective in a natural primate model for human Plasmodium vivax malaria

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.09.060

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2015.09.060

1 reference

4 September 2017

1 reference

PubMed ID

26428453